ReVision Optics Names Two Ophthalmic Experts as Medical Monitors to Oversee Raindrop Near Vision Inlay Clinical Performance

Print 06 September 2017

LAKE FOREST, Calif.--(BUSINESS WIRE)-- ReVision Optics, Inc. (RVO), a leader in implantable presbyopia-correcting corneal inlay technology, announces that Bret Fisher, M.D. and Sumit (Sam) Garg, M.D. will serve as co-medical monitors to oversee the clinical performance of the Company’s Raindrop® Near Vision Inlay, a novel corneal inlay for the surgical correction of presbyopia approved by the U.S. Food and Drug Administration (FDA) in June 2016. Drs. Fisher and Garg are assuming the responsibilities previously handled by Roger F. Steinert, M.D., who passed away on June 6, 2017, and Douglas D. Koch, M.D., Professor and Allen, Mosbacher, and Law Chair of the Ophthalmology Department at Baylor College of Medicine in Houston.

Background on ReVision Optics’ new medical monitors are as follows:

  • Dr. Fisher serves as Medical Director of the Eye Center of North Florida, specializing in refractive and cataract surgery. He is board certified by the American Board of Ophthalmology and certified in Cataract and Implant Surgery and LASIK by the American College of Eye Surgeons, as well as an active member of the American Society of Cataract and Refractive Surgery (ASCRS). The Eye Center of North Florida is nationally recognized as an ophthalmic center of excellence and frequently hosts visiting surgeons from across the U.S. and the world. Dr. Fisher has served as a clinical investigator for more than 30 refractive surgery studies and is a frequent speaker at industry conferences.
  • Dr. Garg is Vice Chair of Clinical Ophthalmology, Medical Director, and Associate Professor in Cataract, Refractive, and External Disease and Corneal Surgery at the Gavin Herbert Eye Institute at the University of California, Irvine. He is involved in numerous research projects and actively participates in research related to refractive surgery. Dr. Garg has authored numerous book chapters, including the textbook Ophthalmic Microsurgery: Principles, Techniques, and Applications, and currently serves as chair of the ASCRS Young Eye Surgeons clinical committee and as co-medical eye bank director for SightLife. He has been recognized in Best Doctors and Super Doctors “Rising Stars” yearly since 2013.

“We are clearly delighted to have two highly experienced ophthalmic surgeons in Drs. Fisher and Garg assume responsibility for this important role, bringing extensive academic and practical expertise in overseeing and reviewing outcomes with the Raindrop Inlay procedure,” said John Kilcoyne, CEO of ReVision Optics. “We are deeply saddened by the passing of Dr. Roger Steinert, who was a distinguished ophthalmologist and internationally recognized authority on corneal and refractive surgery. We are highly appreciative of the dedication and stringent standards that he and Dr. Douglas Koch, also a highly respected authority in refractive surgery, brought to this function.”

“It has been my pleasure to serve as medical monitor through the Raindrop Near Vision Inlay FDA-approval process, but it is now time to pass the baton so I can focus on my growing responsibilities at Baylor,” said Dr. Koch. “My first-hand experience monitoring the outstanding patient outcomes clearly shows the Raindrop Near Vision Inlay as a viable solution to correcting the visual acuity of many who have difficulty with near vision due to presbyopia.”

“We are pleased with the reception we are receiving to the Raindrop Near Vision Inlay, having now completed nearly 2,000 procedures with a high rate of positive patient outcomes and bringing the WOW factor to those with presbyopia,” said Kilcoyne. “Interestingly, many ophthalmic surgeons tell us that adding the Raindrop Inlay procedure to their toolbox is having the positive impact of driving patients to their practices for Raindrop and other refractive procedures and treatments.”

About the Raindrop Near Vision Inlay

The Raindrop Near Vision Inlay is placed in the cornea of the non-dominant eye during a 10-minute procedure. The Raindrop is comprised of approximately 80% water and has a refractive index very similar to the cornea. It is transparent and therefore does not restrict the amount of light reaching the retina. The reshaping of the anterior curvature of the cornea improves near vision.

The Raindrop Near Vision Inlay has received approval by the U.S. Food and Drug Administration, authorization to affix the CE Mark for the European Union, license approval by the Ministry of Food and Drug Safety (South Korea), approval by the Therapeutic Goods Administration (Australia) and registration with the Medicines and Medical Safety Authority (New Zealand). Other country-specific registrations are pending.

About ReVision Optics

ReVision Optics, Inc. focuses on the development and commercialization of innovative optical solutions dedicated to presbyopic vision correction. The company’s Raindrop Near Vision Inlay offers a unique, patented refractive surgery solution. The Raindrop improves near vision that has been lost through the eye’s natural aging process called presbyopia. The Raindrop Near Vision Inlay provides an ideally suited surgical option for near-vision enhancement. 

Return

All Partners

All Portfolio

MEDIA CENTER

  • NovaMedica began construction of a pharmaceutical plant in the Kaluga region

    NovaMedica began construction of a pharmaceutical plant in the Kaluga region

    Russian pharmaceutical company NovaMedica, a portfolio company of RUSNANO, announces the start of construction of a plant for the production of sterile injectable drugs as part of its long-term strategy to localize innovative medicines and technologies of their development and production in Russia. The plant will be built in the industrial park “Vorsino” in the Kaluga region.

All news